UNSPSC 51371802: Ketobemidone

This classification denotes an opioid receptor agonist with the molecular formula C15H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PQS1L514CF, chemically known as 1-propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8ci) but generally known as ketobemidone, which bears US NIH Compound Identifier 10101. European Medicines Agency schedules Ketobemidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08370MIG. The term KETOBEMIDONE is an International Non-Proprietary Name.

UNSPSC 51371802 Ketobemidone is a Commodity code that in recent state and local procurement activity covers pharmaceutical and drug-management products and services, though the recent opportunities tagged to it diverge from the code's nominal scope. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, while the Texas Health and Human Services Commission posted a Request for Information in April 2026 exploring direct-to-manufacturer pharmacy prescriptions for its Therapeutic Pharmacy Initiative, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP in January 2026 for generic multi-source pharmaceuticals and over-the-counter products available through three authorized wholesalers. The issuing-body mix spans county health departments (Seminole County), state health and human services agencies (Texas HHS), and cooperative purchasing alliances serving multiple state jurisdictions (MMCAP). Solicitations under this code reflect procurement by state agencies and county governments for pharmaceutical supply and distribution, though the recent opportunities show limited direct alignment with ketobemidone specifically.

Recent activity concentrates in Florida, Texas, and Minnesota, with the MMCAP cooperative also covering Oregon. The Seminole County IFB (due July 26, 2026) requires vendors to submit electronic bids with unit pricing, maintain workers' compensation and commercial general liability coverage, and complete deliveries within three months under a two-year initial term with optional one-year renewal; the contract may be FEMA-funded, triggering federal compliance requirements. The MMCAP RFP (proposals due March 26, 2026) establishes multi-award contracts for manufacturers with pricing evaluated on competitiveness (75 percent weight), fixed pricing (10 percent), EDI capability (5 percent), and administrative fee compliance (5 percent), requiring vendors to maintain relationships with at least two of three authorized wholesalers and comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act. The Texas RFI functioned as preliminary market intelligence gathering rather than a competitive solicitation, designed to inform future formal procurement strategy for direct manufacturer relationships outside traditional pharmacy benefit manager and group purchasing organization channels.